Journal Article Epublish
PubMed: 40045981 DOI: 10.1093/jscdis/yoaf003
Nocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study.
J Sick Cell Dis 2(1):yoaf003
Authors: Mofiyin A Obadina, Iman Owens, Ada Chang, Vanessa Miller, Jane A Little
Affiliations
- Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, United States.
- UNC Blood Research Center, University of North Carolina, Chapel Hill, NC 27514, United States.
- UNC Gillings School of Public Health, University of North Carolina, Chapel Hill, NC 27514, United States.
Abstract
High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO 2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO 2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.
MeSH
Cells, Hemoglobins, Erythrocytes, Blood, Anemia, Sickle Cell, Retrospective Studies, Blood Cells, Therapeutics